Biotherapeutics News for January 2019

New migraine drug not cost-effective NICE says in draft guidance New migraine drug not cost-effective NICE says in draft guidance

NICE has today (10 January) published draft guidance for public consultation which does not recommend erenumab (Aimovig, Novartis) for preventing migraine.
10 January, 2019